0.00Open0.00Pre Close0 Volume0 Open Interest23.00Strike Price0.00Turnover0.00%IV79.83%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.66Leverage Ratio--Theta--Rho--Eff Leverage--Vega
uniQure NV Stock Discussion
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
Revolutionary Gene Therapy for Huntington's Disease Earns FDA Breakthrough Status After Promising Trial Results
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
Benzinga· 23 mins ago
Revolutionary Hemophilia B Treatment Eliminates Need for Regular Therapy in 94% of Patients
share your thoughts & ideas explain why 2025 will be amazing several break free and run
apextradez Wins so can you
No comment yet